519 related articles for article (PubMed ID: 25146530)
1. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
Lim HJ; Crowe P; Yang JL
J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
Barrett D; Brown VI; Grupp SA; Teachey DT
Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
[TBL] [Abstract][Full Text] [Related]
3. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
4. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
LoRusso PM
J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
[TBL] [Abstract][Full Text] [Related]
6. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.
Rafii S; Roda D; Geuna E; Jimenez B; Rihawi K; Capelan M; Yap TA; Molife LR; Kaye SB; de Bono JS; Banerji U
Clin Cancer Res; 2015 Apr; 21(8):1869-76. PubMed ID: 25649020
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of the PI3K/AKT/mTOR pathway in human malignancies; trend of current clinical trials.
Davoodi-Moghaddam Z; Jafari-Raddani F; Delshad M; Pourbagheri-Sigaroodi A; Bashash D
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15293-15310. PubMed ID: 37594532
[TBL] [Abstract][Full Text] [Related]
8. PARK2 Depletion Connects Energy and Oxidative Stress to PI3K/Akt Activation via PTEN S-Nitrosylation.
Gupta A; Anjomani-Virmouni S; Koundouros N; Dimitriadi M; Choo-Wing R; Valle A; Zheng Y; Chiu YH; Agnihotri S; Zadeh G; Asara JM; Anastasiou D; Arends MJ; Cantley LC; Poulogiannis G
Mol Cell; 2017 Mar; 65(6):999-1013.e7. PubMed ID: 28306514
[TBL] [Abstract][Full Text] [Related]
9. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
Mohite R; Doshi G
Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges.
Cheaib B; Auguste A; Leary A
Chin J Cancer; 2015 Jan; 34(1):4-16. PubMed ID: 25556614
[TBL] [Abstract][Full Text] [Related]
11. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Markman B; Dienstmann R; Tabernero J
Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
[TBL] [Abstract][Full Text] [Related]
13. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt-mediated regulation of p53 in cancer.
Abraham AG; O'Neill E
Biochem Soc Trans; 2014 Aug; 42(4):798-803. PubMed ID: 25109960
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations.
LoPiccolo J; Blumenthal GM; Bernstein WB; Dennis PA
Drug Resist Updat; 2008; 11(1-2):32-50. PubMed ID: 18166498
[TBL] [Abstract][Full Text] [Related]
16. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A; Foo ASC; Lam HY; Yap KCH; Jacot W; Jones RH; Eng H; Nair MG; Makvandi P; Geoerger B; Kulke MH; Baird RD; Prabhu JS; Carbone D; Pecoraro C; Teh DBL; Sethi G; Cavalieri V; Lin KH; Javidi-Sharifi NR; Toska E; Davids MS; Brown JR; Diana P; Stebbing J; Fruman DA; Kumar AP
Mol Cancer; 2023 Aug; 22(1):138. PubMed ID: 37596643
[TBL] [Abstract][Full Text] [Related]
17. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models.
Gómez V; Galazi M; Weitsman G; Monypenny J; Al-Salemee F; Barber PR; Ng K; Beatson R; Szokol B; Orfi L; Mullen G; Vanhaesebroeck B; Chowdhury S; Leung HY; Ng T
Mol Cancer Ther; 2022 Apr; 21(4):667-676. PubMed ID: 35086953
[TBL] [Abstract][Full Text] [Related]
18. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
Sacco A; Roccaro A; Ghobrial IM
Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
[TBL] [Abstract][Full Text] [Related]
19. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
Westin JR
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):335-42. PubMed ID: 24650973
[TBL] [Abstract][Full Text] [Related]
20. The role of ubiquitination and deubiquitination in PI3K/AKT/mTOR pathway: A potential target for cancer therapy.
Jin J; He J; Li X; Ni X; Jin X
Gene; 2023 Dec; 889():147807. PubMed ID: 37722609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]